Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2031-2040

  Kim, Bongsu ^a   Abdel Rahman, Mohamed H ^a,b,c   Wang, Tiffany ^a   Pouly, Severin ^a   Mahmoud, Ashraf M ^a   Cebulla, Colleen M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Extracellular matrix; Matrix metalloproteinase; MMP 12; MMP 13; Proliferative vitreoretinopathy; Retinal detachment; Spectral domain optical coherence tomography; TIMP 1; TIMP 2; Tissue inhibitor metalloproteinase

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FIBROSIS; GENE EXPRESSION; GLIOSIS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA DETACHMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VITREORETINOPATHY; WESTERN BLOTTING;

EXTRACELLULAR MATRIX; MATRIX METALLOPROTEINASE; MMP-12; MMP-13; PROLIFERATIVE VITREORETINOPATHY; RETINAL DETACHMENT; SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TIMP-1; TIMP-2; TISSUE INHIBITOR METALLOPROTEINASE;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL DETACHMENT; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84898756527     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13374     Document Type: Article

References (51)

1. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. Arch Ophthalmol. 1982;100:289-292.
2. Asaria RH, Charteris DG. Proliferative vitreoretinopathy: developments in pathogenesis and treatment. Compr Ophthalmol Update. 2006;7:179-185.
3. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004;137:1105-1115.
4. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21:127-144.
5. Jalali S. Retinal detachment. Community Eye Health. 2003;16: 25-26.
6. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31: 14-28.
7. Charteris DG, Downie J, Aylward GW, Sethi C, Luthert P. Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2007; 245:93-100.
8. Charteris DG, Hiscott P, Grierson I, Lightman SL. Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes. Ophthalmology. 1992;99:1364-1367.
9. Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, Grierson I. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology. 1993;100:43-46.
10. Sethi CS, Lewis GP, Fisher SK, et al. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2005;46: 329-342.
11. Ala-aho R, Kahari VM. Collagenases in cancer. Biochimie. 2005;87:273-286.
12. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis. 2001;21: 373-384.
13. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108-2114.
14. Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178:5288-5295.
15. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993;268:23824-23829.
16. Yu J, Peng R, Chen H, Cui C, Ba J. Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis. Invest Ophthalmol Vis Sci. 2012;53:8146-8153.
17. Lecomte J, Louis K, Detry B, et al. Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci. 2011;68:677-686.
18. Qin L, Han YP. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am J Pathol. 2010;177:1915-1928.
19. Kim EJ, Cho HJ, Park D, et al. Antifibrotic effect of MMP13-encoding plasmid DNA delivered using polyethylenimine shielded with hyaluronic acid. Mol Ther. 2011;19:355-361.
20. Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006;44:420-429.
21. Nakazawa T, Takeda M, Lewis GP, et al. Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci. 2007;48:2760-2768.
22. Luna G, Kjellstrom S, Verardo MR, et al. The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. Invest Ophthalmol Vis Sci. 2009;50:3977-3984.
23. Verardo MR, Lewis GP, Takeda M, et al. Abnormal reactivity of Muller cells after retinal detachment in mice deficient in GFAP and vimentin. Invest Ophthalmol Vis Sci. 2008;49:3659-3665.
24. Cebulla CM, Ruggeri M, Murray TG, Feuer WJ, Hernandez E. Spectral domain optical coherence tomography in a murine retinal detachment model. Exp Eye Res. 2010;90:521-527.
25. Abdel-Rahman MH, Craig EL, Davidorf FH, Eng C. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin Cancer Res. 2005;11:73-78.
26. Ispanovic E, Serio D, Haas TL. Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation. Am J Physiol Cell Physiol. 2008;295:C600-C610.
27. Cebulla CM, Jockovich ME, Pina Y, et al. Basic fibroblast growth factor impact on retinoblastoma progression and survival. Invest Ophthalmol Vis Sci. 2008;49:5215-5221.
28. Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci. 2009;50: 4429-4435.
29. Cebulla CM, Zelinka CP, Scott MA, et al. A chick model of retinal detachment: cone rich and novel. PLoS One. 2012;7: e44257.
30. Fisher SK, Lewis GP, Linberg KA, Verardo MR. Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog Retin Eye Res. 2005; 24:395-431.
31. Fisher SK, Lewis GP. Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res. 2003;43:887-897.
32. Nakazawa T, Hisatomi T, Nakazawa C, et al. Monocyte chemoattractant protein 1 mediates retinal detachmentinduced photoreceptor apoptosis. Proc Natl Acad Sci U S A. 2007;104:2425-2430.
33. Hisatomi T, Sakamoto T, Sonoda KH, et al. Clearance of apoptotic photoreceptors: elimination of apoptotic debris into the subretinal space and macrophage-mediated phagocytosis via phosphatidylserine receptor and integrin alphavbeta3. Am J Pathol. 2003;162:1869-1879.
34. Kaneko H, Nishiguchi KM, Nakamura M, Kachi S, Terasaki H. Characteristics of bone marrow-derived microglia in the normal and injured retina. Invest Ophthalmol Vis Sci. 2008; 49:4162-4168.
35. Lewis GP, Sethi CS, Carter KM, Charteris DG, Fisher SK. Microglial cell activation following retinal detachment: a comparison between species. Mol Vis. 2005;11:491-500.
36. Lewis GP, Charteris DG, Sethi CS, Fisher SK. Animal models of retinal detachment and reattachment: identifying cellular events that may affect visual recovery. Eye. 2002;16:375-387.
37. Anderson DH, Stern WH, Fisher SK, Erickson PA, Borgula GA. Retinal detachment in the cat: the pigment epithelialphotoreceptor interface. Invest Ophthalmol Vis Sci. 1983; 24:906-926.
38. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:1524-1529.
39. Gonzalez-Avila G, Mendez D, Lozano D, Ramos C, Delgado J, Iturria C. Role of retinal detachment subretinal fluid on extracellular matrix metabolism. Ophthalmologica. 2004;218: 49-56.
40. Symeonidis C, Papakonstantinou E, Androudi S, et al. Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy. Cytokine. 2011;54:212-217.
41. Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E. Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol. 2011;89:339-345.
42. Symeonidis C, Diza E, Papakonstantinou E, Souliou E, Dimitrakos SA, Karakiulakis G. Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. Retina. 2007;27:1279-1285.
43. Symeonidis C, Diza E, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA. Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 2007;245:560-568.
44. Coral K, Angayarkanni N, Madhavan J, et al. Lysyl oxidase activity in the ocular tissues and the role of LOX in proliferative diabetic retinopathy and rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 2008;49:4746-4752.
45. De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998;39:1256-1260.
46. Webster L, Chignell AH, Limb GA. Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. Exp Eye Res. 1999;68:91-98.
47. Madlener M. Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds. Arch Dermatol Res. 1998;(suppl 290):S24-S29.
48. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
49. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res. 1999;18:167-190.
50. Hiscott P, Hagan S, Heathcote L, et al. Pathobiology of epiretinal and subretinal membranes: possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). Eye (Lond). 2002;16:393-403.
51. Tang S, Scheiffarth OF, Wildner G, Thurau SR, Lund OE. Lymphocytes, macrophages and HLA-DR expression in vitreal and epiretinal membranes of proliferative vitreoretinopathy. An immunohistochemical study. Ger J Ophthalmol. 1992;1: 176-179.